This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.
Seletracetam
Discontinued UCB Pharma research compound.
Aliases (3)
Overview
What is Seletracetam?
Seletracetam is a third-generation racetam derivative developed by UCB as a successor to levetiracetam and brivaracetam, originally investigated for epilepsy. Development was discontinued, but it remains of interest as a high-affinity SV2A modulator in research circles.
Key Benefits
Reduces neuronal hyperexcitability and seizure-like activity in preclinical models with high potency, may offer neuroprotection, and was projected to have an improved tolerability profile vs older racetams.
Mechanism of Action
Binds with high affinity to synaptic vesicle protein 2A (SV2A) — the same target as levetiracetam — modulating presynaptic vesicle release of neurotransmitters including glutamate. This dampens excessive synaptic firing without significantly affecting baseline transmission.
Pharmacokinetics
▸Brand options2 known
StatusNever approved, never scheduled — investigational only, development discontinued
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety
Unknown beyond what would be inferred from the SV2A class. Levetiracetam and brivaracetam share a class profile of irritability/aggression ("Keppra rage" — well documented for levetiracetam, milder for brivaracetam), somnolence, fatigue, and dose-dependent cognitive slowing. Seletracetam would be expected to share this profile. Whether the higher affinity translates to worse or better neuropsychiatric tolerability is unanswered and will remain so.
References
Seletracetam — DrugBank
basic chemistry, listed status as discontinued investigational.
View StudyMatagne et al. (2010) — Levetiracetam and seletracetam compared (Epilepsia/Curr Pharm Des era reviews)
pre-discontinuation medicinal-chemistry context for the SV2A pipeline.
View StudyUCB Pharma pipeline disclosures, 2007-2009 archived annual reports
public record of the development decision (no longer prominently featured post-discontinuation).
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.